Get the Stockscreener App
1.26
0.79%
-0.01
After Hours:
1.29
0.03
+2.38%
Pds Biotechnology Corporation Stock (PDSB) Latest News
Where Do Analysts Think The PDS Biotechnology Corporation (NASDAQ: PDSB) Is Going - Stocks Register
PDS Biotechnology (NASDAQ:PDSB) Given Buy Rating at HC Wainwright - Defense World
Do you want to know where to find good stock? Take a look at PDS Biotechnology Corporation’s (NASDAQ:PDSB) Sentiment Analysis – US Post News - US Post News
PDS Biotech stock plunges to 52-week low of $1.25 - Investing.com
PDS Biotech Announces Circulating Tumor DNA Results for Versamune® HPV in IMMUNOCERV Trial Published in Clinical Cancer Research - The Manila Times
PDS Biotechnology Reports Promising Phase 2 Results for Versamune® HPV in Treating HPV16-Positive Cancers; Phase 3 Trial Planned for Q1 2025 - Nasdaq
Cancer Breakthrough? PDS Biotech's HPV Treatment Shows Perfect Survival Rate in Latest Trial - StockTitan
PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025 - The Manila Times
Can PDS Biotech's Latest Oncology Developments Transform Cancer Treatment? CEO to Reveal Strategy - StockTitan
PDSB stock touches 52-week low at $1.3 amid market challenges - MSN
Cancer Vaccines Market on Track for Major Expansion in the - GlobeNewswire
Cancer Vaccines Market on Track for Major Expansion in - One News Page
PDSB stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa
PDS Biotechnology (NASDAQ:PDSB) Trading Down 5.8%What's Next? - MarketBeat
PDS Biotech set for Phase 3 trial in HPV-positive cancer treatment - MSN
FDA approves PDS Biotech's Phase 3 trial design for cancer therapy - MSN
PDS Biotechnology (NASDAQ:PDSB) Shares Down 5.8% – What’s Next? - Defense World
Clinical Trials News Live Feed - StockTitan
PDS Biotech reaffirms guidance for clinical trial - ShareCast
PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma - Marketscreener.com
PDS Biotech Advances Novel HPV Cancer Treatment to Phase 3 Trial with FDA Fast Track Status | PDSB Stock News - StockTitan
Tuberculosis Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance
PDS Biotechnology Corporation (NASDAQ: PDSB): Hidden Gems In A Time Of Volatility - Stocks Register
Contrasting PDS Biotechnology (NASDAQ:PDSB) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Head-To-Head Contrast: Bicara Therapeutics (NASDAQ:BCAX) & Lipella Pharmaceuticals (NASDAQ:LIPO) - Defense World
Inspirion Wealth Advisors LLC Sells 270,862 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - MarketBeat
PDSB stock touches 52-week low at $1.51 amid market challenges - Investing.com Nigeria
Spero Therapeutics names Esther Rajavelu as Interim President and CEO (NASDAQ:SPRO) - Seeking Alpha
Geode Capital Management LLC Acquires 37,142 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Ball Co. (NYSE:BALL) Shares Sold by GAMMA Investing LLC - Defense World
PDS Planning Inc Has $23.21 Million Stock Position in Apple Inc. (NASDAQ:AAPL) - Defense World
Immuneering stock jumps on lead asset data (IMRX:NASDAQ) - Seeking Alpha
Meet Gauzy and Research Frontiers at CES This Week to See the Latest in SPD-SmartGlass Products and Technology - Quantisnow
State Street Corp Sells 18,700 Shares of PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Corp Announces Pricing Of Public Offering Of About $12 mln Shares - Reuters
PDS Biotechnology (NASDAQ:PDSB) Receives "Buy" Rating from HC Wainwright - MarketBeat
DBV stock rallies post-market on FDA Viaskin update (NASDAQ:DBVT) - Seeking Alpha
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
PDS Biotech Grants Stock Options to New Clinical Employee Under Inducement Plan - StockTitan
PDSBPDS Biotechnology Corporation Latest Stock News & Market Updates - StockTitan
PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET - The Manila Times
PDS Biotech Announces Expert Panel on HPV16 Cancer Treatment Phase 3 Trial - StockTitan
A share offer that's hard to refuse - Investors Chronicle
BioGene Therapeutics Welcomes Stephen Glover to Its Board of Directors - Newsfile
PreveCeutical Medical Appoints Biopharma Veteran Stephen Glover to BioGene Board - StockTitan
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):